Abstract
Mucopolysaccharidoses are a group of hereditary metabolic diseases, relating to lysosomal storage disorders and caused by a deficiency of the enzymes, involved in degradation of glycosaminoglycans (mucopolysaccharides). Severe forms of mucopolysaccharidoses of types I, II and VII and mucopolysaccharidosis of type III are characterised by primary central nervous system damage and neurodegenerative course of the disease with cognitive decline, behavioural abnormalities and decreased lifespan. Neuropathogenesis of mucopolysaccharidoses is not completely studied. The question of reversibility of cellular damage is still open. There is currently no effective treatment for mucopolysaccharidoses with primary central nervous system damage. Intravenous enzyme replacement therapy doesn’t cross the blood-brain barrier and has no influence on neurodegeneration. Investigation of alternative treatment options, providing delivery of therapeutic agent to central nervous system, is currently being carried out. Preclinical studies of highdose, intrathecal, intraventricular enzyme replacement therapy; administration of modified enzyme, capable of crossing the blood-brain barrier; gene, cell therapies, stop codon readthrough approach and substrate reduction therapy show promising results.
Highlights
Мукополисахаридозы — группа наследственных заболеваний обмена веществ, относящихся к лизосомным болезням накопления и связанных с дефицитом ферментов, расщепляющих гликозаминогликаны
Mucopolysaccharidoses are a group of hereditary metabolic diseases, relating to lysosomal storage disorders and caused by a deficiency of the enzymes, involved in degradation of glycosaminoglycans
Severe forms of mucopolysaccharidoses of types I, II and VII and mucopolysaccharidosis of type III are characterised by primary central nervous system damage and neurodegenerative course of the disease with cognitive decline, behavioural abnormalities and decreased lifespan
Summary
Мукополисахаридозы — группа наследственных заболеваний обмена веществ, относящихся к лизосомным болезням накопления и связанных с дефицитом ферментов, расщепляющих гликозаминогликаны (мукополисахариды). Уменьшение степени выраженности нейропатологических изменений в головном мозге и отложений ГАГ в твердой мозговой оболочке при применении данного метода описаны у экспериментальных мышей, собак и кошек с заданными генетическими свойствами МПС I, II, IIIA [8, 22, 23].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have